Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 2
1969 1
1975 3
1976 1
1978 2
1979 2
1980 6
1981 9
1982 10
1983 9
1984 2
1985 8
1986 9
1987 15
1988 16
1989 12
1990 15
1991 8
1992 6
1993 11
1994 12
1995 10
1996 11
1997 4
1998 3
1999 8
2000 4
2001 4
2002 8
2003 14
2004 3
2005 6
2006 3
2007 2
2008 10
2009 14
2010 16
2011 22
2012 13
2013 11
2014 14
2015 21
2016 12
2017 9
2018 17
2019 14
2020 12
2021 10
2022 12
2023 13
2024 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

437 results

Results by year

Filters applied: . Clear all
Page 1
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.
Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers SK, Secord AA, Havrilesky L, O'Malley DM, Backes F, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi KS, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD. Fader AN, et al. Among authors: schwartz pe. J Clin Oncol. 2018 Jul 10;36(20):2044-2051. doi: 10.1200/JCO.2017.76.5966. Epub 2018 Mar 27. J Clin Oncol. 2018. PMID: 29584549 Clinical Trial.
Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis.
Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers S, Secord AA, Havrilesky L, O'Malley DM, Backes FJ, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi K, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD. Fader AN, et al. Among authors: schwartz pe. Clin Cancer Res. 2020 Aug 1;26(15):3928-3935. doi: 10.1158/1078-0432.CCR-20-0953. Epub 2020 Jun 29. Clin Cancer Res. 2020. PMID: 32601075 Free PMC article. Clinical Trial.
Integrated mutational landscape analysis of uterine leiomyosarcomas.
Choi J, Manzano A, Dong W, Bellone S, Bonazzoli E, Zammataro L, Yao X, Deshpande A, Zaidi S, Guglielmi A, Gnutti B, Nagarkatti N, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Jeong K, Zhao S, Buza N, Hui P, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Odicino F, Pecorelli S, Ardighieri L, Bilguvar K, Quick CM, Silasi DA, Huang GS, Andikyan V, Clark M, Ratner E, Azodi M, Imielinski M, Schwartz PE, Alexandrov LB, Lifton RP, Schlessinger J, Santin AD. Choi J, et al. Among authors: schwartz pe. Proc Natl Acad Sci U S A. 2021 Apr 13;118(15):e2025182118. doi: 10.1073/pnas.2025182118. Proc Natl Acad Sci U S A. 2021. PMID: 33876771 Free PMC article.
In Reply.
Desai VB, Wright JD, Schwartz PE, Gross CP, Xu X. Desai VB, et al. Among authors: schwartz pe. Obstet Gynecol. 2018 Aug;132(2):519-520. doi: 10.1097/AOG.0000000000002770. Obstet Gynecol. 2018. PMID: 30045198 No abstract available.
In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma.
Mutlu L, Manavella DD, Bellone S, McNamara B, Harold JA, Mauricio D, Siegel ER, Buza N, Hui P, Hartwich TMP, Yang-Hartwich Y, Demirkiran C, Verzosa MSZ, Altwerger G, Ratner ES, Huang GS, Clark M, Andikyan V, Azodi M, Dottino PR, Schwartz PE, Santin AD. Mutlu L, et al. Among authors: schwartz pe. Mol Cancer Ther. 2023 Dec 1;22(12):1404-1412. doi: 10.1158/1535-7163.MCT-23-0126. Mol Cancer Ther. 2023. PMID: 37676984
Effect of Exercise on Chemotherapy-Induced Peripheral Neuropathy Among Patients Treated for Ovarian Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Cao A, Cartmel B, Li FY, Gottlieb LT, Harrigan M, Ligibel JA, Gogoi R, Schwartz PE, Esserman DA, Irwin ML, Ferrucci LM. Cao A, et al. Among authors: schwartz pe. JAMA Netw Open. 2023 Aug 1;6(8):e2326463. doi: 10.1001/jamanetworkopen.2023.26463. JAMA Netw Open. 2023. PMID: 37526937 Free PMC article. Clinical Trial.
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
Gelissen JH, Adjei NN, McNamara B, Mutlu L, Harold JA, Clark M, Altwerger G, Dottino PR, Huang GS, Santin AD, Azodi M, Ratner E, Schwartz PE, Andikyan V. Gelissen JH, et al. Among authors: schwartz pe. Ann Surg Oncol. 2023 Sep;30(9):5597-5609. doi: 10.1245/s10434-023-13757-0. Epub 2023 Jun 26. Ann Surg Oncol. 2023. PMID: 37358686 Review.
Leukemias.
Pejovic T, Schwartz PE. Pejovic T, et al. Among authors: schwartz pe. Clin Obstet Gynecol. 2002 Sep;45(3):866-78. doi: 10.1097/00003081-200209000-00033. Clin Obstet Gynecol. 2002. PMID: 12370628 Review. No abstract available.
Review of Leiomyoma Variants.
Arleo EK, Schwartz PE, Hui P, McCarthy S. Arleo EK, et al. Among authors: schwartz pe. AJR Am J Roentgenol. 2015 Oct;205(4):912-21. doi: 10.2214/AJR.14.13946. AJR Am J Roentgenol. 2015. PMID: 26397344 Review.
Leiomyosarcomas: clinical presentation.
Schwartz LB, Diamond MP, Schwartz PE. Schwartz LB, et al. Among authors: schwartz pe. Am J Obstet Gynecol. 1993 Jan;168(1 Pt 1):180-3. doi: 10.1016/s0002-9378(12)90910-2. Am J Obstet Gynecol. 1993. PMID: 8420323 Review.
437 results